SOUTH SAN FRANCISCO, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...
Proven commercial leader with broad global experience in building and running commercial organizations and successfully launching products for people with neurological and rare diseases SOUTH SAN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback